Risk factors for the development of psoriasis
K Kamiya, M Kishimoto, J Sugai, M Komine… - International journal of …, 2019 - mdpi.com
Psoriasis is an immune-mediated genetic skin disease. The underlying pathomechanisms
involve complex interaction between the innate and adaptive immune system. T cells …
involve complex interaction between the innate and adaptive immune system. T cells …
Disease modification in inflammatory skin disorders: opportunities and challenges
T Bieber - Nature Reviews Drug Discovery, 2023 - nature.com
Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …
Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems
Whereas the cellular and molecular features of human inflammatory skin diseases are well
characterized, their tissue context and systemic impact remain poorly understood. We thus …
characterized, their tissue context and systemic impact remain poorly understood. We thus …
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Background Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …
Psoriasis: comorbidities
F Yamazaki - The Journal of dermatology, 2021 - Wiley Online Library
Psoriasis has long been known as a disease with many complications, but was attributed to
diet and obesity. However, in recent years, psoriasis itself has been recognized as a series …
diet and obesity. However, in recent years, psoriasis itself has been recognized as a series …
Old and new biological therapies for psoriasis
K Rønholt, L Iversen - International journal of molecular sciences, 2017 - mdpi.com
Biological therapy became available for psoriasis with the introduction of alefacept at the
beginning of this century. Up to then, systemic treatment options comprised small molecule …
beginning of this century. Up to then, systemic treatment options comprised small molecule …
Psoriasis and obesity
P Jensen, L Skov - Dermatology, 2017 - karger.com
Psoriasis is a common chronic inflammatory skin disease with a complex pathogenesis
consisting of a genetic component, immune dysfunction, and environmental factors. It is …
consisting of a genetic component, immune dysfunction, and environmental factors. It is …
Hyperhomocysteinemia as a risk factor and potential nutraceutical target for certain pathologies
C Tinelli, A Di Pino, E Ficulle, S Marcelli… - Frontiers in …, 2019 - frontiersin.org
Hyperhomocysteinemia is recognized as a risk factor for several diseases, including
cardiovascular and neurological conditions. Homocysteine (HCys) is a key metabolite …
cardiovascular and neurological conditions. Homocysteine (HCys) is a key metabolite …
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
JJ Wu, A Kavanaugh, MG Lebwohl… - Journal of the …, 2022 - Wiley Online Library
Psoriasis is a chronic systemic inflammatory disorder associated with several comorbidities
in addition to the characteristic skin lesions. Metabolic syndrome (MetS) is the most frequent …
in addition to the characteristic skin lesions. Metabolic syndrome (MetS) is the most frequent …
[HTML][HTML] The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies
AW Armstrong, CT Harskamp, EJ Armstrong - Nutrition & diabetes, 2012 - nature.com
Objective: Psoriasis is an inflammatory skin disease affecting 2–4% of the world population.
The objective of this study was to perform a systematic review and meta-analysis …
The objective of this study was to perform a systematic review and meta-analysis …